Baricitinib is the first JAK inhibitor approved in the US and Europe for the treatment of severe alopecia areata. In the UK the national institute for health and care excellence NICE evaluates new “technologies” for their efficacy and cost effectiveness and decides whether the NHS will pay for the treatment.
You can view the draft guidance by NICE here.
This is not the final outcome but at this stage NICE is NOT approving this treatment in the NHS. The reasons for this are explained by Alopecia UK
There is an opportunity to make comments until 20th March 2023 and I would encourage any patients with Alopecia but particularly any of my patients who have experienced dramatic hair regrowth to make comments on how this has improved their condition and the quality of their life. To make a comment you will need to register for an account with NICE and then fill in the form .